| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. | JAMA | 2011 | 4.63 |
| 2 | Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. | J Clin Oncol | 2010 | 1.56 |
| 3 | The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. | Breast Cancer Res Treat | 2009 | 1.41 |
| 4 | Discussion of the do-not-resuscitate order: a pilot study of perceptions of patients with refractory cancer. | Support Care Cancer | 2002 | 1.02 |